 |
인쇄하기
취소
|
Korean drugmakers eye generic Exforge development
Korean pharmaceutical firms are gearing up to enter the ever-growing combination antihypertensive drugs market dominated by foreign drug companies – Novartis, Daiichi Sankyo and Boehringer Ingelhiem.
The patent of the market leader, Novartis’s Exforge, is set to expire in September 2012, allowing for its generic versions here.
Exforge contains two prescription medicines: amlodipine, a cal...
The patent of the market leader, Novartis’s Exforge, is set to expire in September 2012, allowing for its generic versions here.
Exforge contains two prescription medicines: amlodipine, a cal...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.